198 related articles for article (PubMed ID: 30086074)
1. Establishment and characterization of melanoma patient-derived xenograft models for preclinical evaluation of novel therapeutics.
Yan J; Wu X; Yu J; Ma M; Yu H; Xu T; Tang H; Xu L; Dai J; Si L; Chi Z; Sheng X; Cui C; Guo J; Kong Y
Melanoma Res; 2018 Dec; 28(6):527-535. PubMed ID: 30086074
[TBL] [Abstract][Full Text] [Related]
2. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis.
Kageyama K; Ohara M; Saito K; Ozaki S; Terai M; Mastrangelo MJ; Fortina P; Aplin AE; Sato T
J Transl Med; 2017 Jun; 15(1):145. PubMed ID: 28645290
[TBL] [Abstract][Full Text] [Related]
3. Validation of a preclinical model for assessment of drug efficacy in melanoma.
Delyon J; Varna M; Feugeas JP; Sadoux A; Yahiaoui S; Podgorniak MP; Leclert G; Dorval SM; Dumaz N; Soulie J; Janin A; Mourah S; Lebbé C
Oncotarget; 2016 Mar; 7(11):13069-81. PubMed ID: 26909610
[TBL] [Abstract][Full Text] [Related]
4. Repurposing Ponatinib as a Potent Agent against
Han Y; Gu Z; Wu J; Huang X; Zhou R; Shi C; Tao W; Wang L; Wang Y; Zhou G; Li J; Zhang Z; Sun S
Theranostics; 2019; 9(7):1952-1964. PubMed ID: 31037149
[No Abstract] [Full Text] [Related]
5. Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor.
Yan J; Wu X; Yu J; Yu H; Xu T; Brown KM; Bai X; Dai J; Ma M; Tang H; Si L; Chi Z; Sheng X; Cui C; Kong Y; Guo J
Eur J Cancer; 2018 Jan; 89():90-101. PubMed ID: 29245078
[TBL] [Abstract][Full Text] [Related]
6. Establishment of Novel Gastric Cancer Patient-Derived Xenografts and Cell Lines: Pathological Comparison between Primary Tumor, Patient-Derived, and Cell-Line Derived Xenografts.
Kuwata T; Yanagihara K; Iino Y; Komatsu T; Ochiai A; Sekine S; Taniguchi H; Katai H; Kinoshita T; Ohtsu A
Cells; 2019 Jun; 8(6):. PubMed ID: 31207870
[TBL] [Abstract][Full Text] [Related]
7. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
[No Abstract] [Full Text] [Related]
8. Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps.
Ilie M; Nunes M; Blot L; Hofman V; Long-Mira E; Butori C; Selva E; Merino-Trigo A; Vénissac N; Mouroux J; Vrignaud P; Hofman P
Cancer Med; 2015 Feb; 4(2):201-11. PubMed ID: 25470237
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations.
Friedman AA; Xia Y; Trippa L; Le LP; Igras V; Frederick DT; Wargo JA; Tanabe KK; Lawrence DP; Neuberg DS; Flaherty KT; Fisher DE
Clin Cancer Res; 2017 Aug; 23(16):4680-4692. PubMed ID: 28446504
[No Abstract] [Full Text] [Related]
10. Establishment and genetically characterization of patient-derived xenograft models of cervical cancer.
Zou S; Ye M; Zhang JA; Ji H; Chen Y; Zhu X
BMC Med Genomics; 2022 Sep; 15(1):191. PubMed ID: 36076209
[TBL] [Abstract][Full Text] [Related]
11. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.
Jäger W; Xue H; Hayashi T; Janssen C; Awrey S; Wyatt AW; Anderson S; Moskalev I; Haegert A; Alshalalfa M; Erho N; Davicioni E; Fazli L; Li E; Collins C; Wang Y; Black PC
Oncotarget; 2015 Aug; 6(25):21522-32. PubMed ID: 26041878
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of a non-gestational choriocarcinoma patient-derived xenograft model.
Oda Y; Niimi K; Yoshida K; Tamauchi S; Yokoi A; Yasui Y; Nishiko Y; Shibata M; Shimizu Y; Yoshihara M; Ikeda Y; Yoshikawa N; Nishino K; Yamamoto E; Kajiyama H
BMC Cancer; 2023 Nov; 23(1):1103. PubMed ID: 37957624
[TBL] [Abstract][Full Text] [Related]
13. Establishment and evaluation of retroperitoneal liposarcoma patient-derived xenograft models: an ideal model for preclinical study.
Xu C; Yan L; An Q; Zhang S; Guan X; Wang Z; Lv A; Liu D; Liu F; Dong B; Zhao M; Tian X; Hao C
Int J Med Sci; 2022; 19(8):1241-1253. PubMed ID: 35928724
[TBL] [Abstract][Full Text] [Related]
14. Establishment and preclinical application of a patient-derived xenograft model for uterine cancer.
Jeong SY; Cho YJ; Ryu JY; Choi JJ; Hwang JR; Kim B; Lee YY; Kim HS; Lee JW
Gynecol Oncol; 2021 Jul; 162(1):173-181. PubMed ID: 33972086
[TBL] [Abstract][Full Text] [Related]
15. Establishment and genomic characterizations of patient-derived esophageal squamous cell carcinoma xenograft models using biopsies for treatment optimization.
Zou J; Liu Y; Wang J; Liu Z; Lu Z; Chen Z; Li Z; Dong B; Huang W; Li Y; Gao J; Shen L
J Transl Med; 2018 Jan; 16(1):15. PubMed ID: 29370817
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient's response to conventional and novel therapies.
Liu L; Wu M; Huang A; Gao C; Yang Y; Liu H; Jiang H; Yu L; Huang Y; Wang H
J Transl Med; 2023 Sep; 21(1):611. PubMed ID: 37689699
[TBL] [Abstract][Full Text] [Related]
17. Establishment of patient-derived cancer xenografts in immunodeficient NOG mice.
Chijiwa T; Kawai K; Noguchi A; Sato H; Hayashi A; Cho H; Shiozawa M; Kishida T; Morinaga S; Yokose T; Katayama M; Takenaka N; Suemizu H; Yamada R; Nakamura Y; Ohtsu T; Takano Y; Imai K; Miyagi Y; Nakamura M
Int J Oncol; 2015 Jul; 47(1):61-70. PubMed ID: 25963555
[TBL] [Abstract][Full Text] [Related]
18. Candidate therapeutic agents in a newly established triple wild-type mucosal melanoma cell line.
Shi C; Gu Z; Xu S; Ju H; Wu Y; Han Y; Li J; Li C; Wu J; Wang L; Li J; Zhou G; Ye W; Ren G; Zhang Z; Zhou R
Cancer Commun (Lond); 2022 Jul; 42(7):627-647. PubMed ID: 35666052
[TBL] [Abstract][Full Text] [Related]
19. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract][Full Text] [Related]
20. Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification.
Oh DY; Jung K; Song JY; Kim S; Shin S; Kwon YJ; Oh E; Park WY; Song SY; Choi YL
BMC Cancer; 2017 Aug; 17(1):535. PubMed ID: 28806950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
